Phathom Pharmaceuticals, Inc.
NMS: PHATLive Quote
📈 ZcoreAI Score
Our AI model analyzes Phathom Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PHAT Z-Score →About Phathom Pharmaceuticals, Inc.
Healthcare
Biotechnology
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
📊 Fundamental Analysis
Phathom Pharmaceuticals, Inc. demonstrates a profit margin of -126.3%, which is below the sector average, suggesting competitive pressure.
The company recently reported 94.1% revenue growth, which is well above average for the Healthcare sector.
At a current price of $12.63, PHAT currently sits at the 65th percentile of its 52-week range (Range: $2.21 - $18.31).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Revenue Growth
Excellent
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$1.00B
Trailing P/E
--
Forward P/E
8.18
Beta (5Y)
0.61
52W High
$18.31
52W Low
$2.21
Avg Volume
1.06M
Day High
Day Low